<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690129</url>
  </required_header>
  <id_info>
    <org_study_id>treatment of miscarraige</org_study_id>
    <nct_id>NCT02690129</nct_id>
  </id_info>
  <brief_title>Vaginal Progesterone for Treatment of Threatened Miscarriage</brief_title>
  <acronym>VPM</acronym>
  <official_title>Vaginal Progesterone for Treatment of Threatened Miscarriage; Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omar Mamdouh Shaaban</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy of vaginal micronized progesterone in the
      treatment of threatened miscarriage. All eligible pregnant women will be randomized to either
      receive vaginal progesterone or no treatment.Evaluation will be two weeks after intervention,
      then every 4 weeks up to 28 weeks gestation or termination of pregnancy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Miscarriage rate up to 28 weeks of gestation</measure>
    <time_frame>Completed 28th week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery or termination of pregnancy</measure>
    <time_frame>Number of completed weeks at the time of delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Threatened Miscarriage</condition>
  <arm_group>
    <arm_group_label>Group I (Progesterone Group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Complete bed rest as an in/or out- patient, according to patient's preference for first 48-72 hours.
Vaginal progesterone treatment as single daily dose of natural micronized progesterone (Prontogest Â® 200 mg) at bedtime for 15 days.
If needed, a pain killer as Indomethacin 50 mg/ rectally twice daily up to control of uterine colic .
Complete abstaining from sexual activity or strenuous effort. Additionally, Rh-ve women with established viable fetuses and continue bleeding will be given a shot of anti-D immunoglobulin 300 ugm/IM ; after 12 weeks' gestation or if undergo surgical evacuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II ( Control group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will follow the same plan of management without progesterone support.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal Progesteron</intervention_name>
    <arm_group_label>Group I (Progesterone Group)</arm_group_label>
    <arm_group_label>Group II ( Control group)</arm_group_label>
    <other_name>Progesterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant with gestational age less than 24 weeks

          2. Presented by bleeding with or without pain

          3. Single viable fetus (confirmed by Ultrasound examination)

          4. Accepting to have vaginal medication

        Exclusion Criteria:

          1. Currently under medication for any chronic diseases (DM, thyroid, liver, renal,
             cardiac and autoimmune disease).

          2. Hypersensitivity to progesterone

          3. Any documented congenital fetal anomaly in the current pregnancy

          4. Women received hormonal treatment in the current pregnancy

          5. Patients conceived via ART
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Omar M Shaaban, MD</last_name>
    <phone>+201223971457</phone>
    <email>omshaaban2000@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hany Abdel-aleem, MD</last_name>
    <phone>+2088414927</phone>
    <email>aleemh@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hany Abdel-Aleem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omar M Shaaban, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Omar Mamdouh Shaaban</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>progesterone</keyword>
  <keyword>threatened abortion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Threatened</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

